News

  • November 14, 2019 - Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia Read More
  • September 16, 2019 - Everest Medicines Expands Senior Leadership Team Read More
  • June 10, 2019 - Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore Read More
  • June 9, 2019 - With Industry's Growing Kidney Moment, Everest Begins Building Kidney Portfolio Read More
  • May 10, 2019 - Everest Medicines Appoints Wende Chen as Chief Commercial Officer Read More
  • April 29, 2019 - Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan Read More
  • January 7, 2019 - Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial Read More
  • September 25, 2018 - VenatoRx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133 Read More
  • August 27, 2018 - Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI) Read More
  • June 25, 2018 - Everest Medicines Subsidiary Acquires Exclusive Worldwide License to Develop and Commercialize Clinical Stage Novel FGFR4 Kinase Inhibitor Read More
  • June 24, 2018 - Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital Read More
  • June 4, 2018 — Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration Read More
  • February 20, 2018 — Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China. Read More
  • December 5, 2017 — Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China. Read More
  • October 27, 2017 — C-Bridge Capital - Investing in China’s health care opportunity. Read More